A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Ganaxolone (Primary)
- Indications Epilepsy
- Focus Registrational; Therapeutic Use
- Acronyms MARIGOLD
- Sponsors Marinus Pharmaceuticals
- 19 Nov 2018 According to Marinus Pharmaceuticals media release,data from this study will be presented at the American Epilepsy Society (AES) Annual Meeting.
- 19 Jun 2018 Status changed from planning to recruiting, according to a Marinus Pharmaceuticals media release.
- 12 Mar 2018 New trial record